𝔖 Bobbio Scriptorium
✦   LIBER   ✦

DOE grants for fuel cell research in small firms

Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
91 KB
Volume
2006
Category
Article
ISSN
1464-2859

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

DOE awards for small business fuel cell
DOE awards for small business fuel cell R&D
πŸ“‚ Article πŸ“… 2004 πŸ› Elsevier Science 🌐 English βš– 71 KB

Protonex has been working closely with the military since 2001 to develop long-duration power solutions for portable applications. It is in the process of commercializing a family of products in the power range from 10 to 1000 We. The company is

Higher funding for fuel cells, hydrogen
Higher funding for fuel cells, hydrogen in 2006 DOE budget proposal
πŸ“‚ Article πŸ“… 2005 πŸ› Elsevier Science 🌐 English βš– 73 KB

United Defense, Battelle demonstrate prototype APU for army vehicle I n the US, Battelle and United Defense Industries have joined forces to develop and demonstrate a prototype fuel cell auxiliary power unit (APU) on a Bradley Fighting Vehicle. The APU is designed to increase vehicle fuel efficiency

Twenty-five years of clinical research f
Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America : Meaningful improvements in survival
✍ Pasi A. JΓ€nne; Boris Freidlin; Scott Saxman; David H. Johnson; Robert B. Livings πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 119 KB πŸ‘ 2 views

## Abstract ## BACKGROUND To determine the changes in clinical trials and outcomes of patients with limited‐stage small cell lung carcinoma (SCLC) treated on Phase III randomized trials initiated in North America between 1972 and1992. ## METHODS Phase III trials from 1972 to 1992 for patients wi

Inhibition of Flt3-activating mutations
Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors
✍ Emilio Siendones; Nuria Barbarroja; Luis ArΓ­stides Torres; Paula BuendΓ­a; Franci πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 344 KB πŸ‘ 1 views

## Abstract The Flt3 receptor tyrosine kinase is a critical mediator in the pathogenesis of acute myeloid leukaemia (AML). Flt3‐activating mutations have been associated with poor prognosis and decreased overall survival of AML patients, thus Flt3 constitutes an ideal target for drug treatment of s